Table 2.

 Frequency of IGHV genes expressed in leukemic cells of Iranian CLL patients

No	IGHV	Total	Mutated (n = 56)	Unmutated (n = 31)	Non‐progressive (n = 44)	Progressive (n = 40)
1	IGHV3‐7	11 (12.6)	9 (16.1)	2 (6.5)	9 (20.5)	2 (5)
2	IGHV3‐30	10 (11.5)	5 (8.9)	5 (16.1)	5 (11.4)	5 (12.5)
3	IGHV3‐48	8 (9.2)	6 (10.7)	2 (6.5)	5 (11.4)	3 (7.5)
4	IGHV4‐39	6 (6.9)	5 (8.9)	1 (3.2)	3 (6.8)	3 (7.5)
5	IGHV1‐8	6 (6.9)	5 (8.9)	1 (3.2)	2 (4.5)	3 (7.5)
6	IGHV4‐34	5 (5.7)	5 (8.9)	0	3 (6.8)	2 (5)
7	IGHV3‐33	5 (5.7)	2 (3.6)	3 (9.7)	3 (6.8)	2 (5)
8	IGHV1‐69	5 (5.7)	1 (1.8)	4 (12.9)	3 (6.8)	2 (5)
9	IGHV3‐23	4 (4.6)	3 (5.4)	1 (3.2)	4 (9.1)	0
10	IGHV1‐2	3 (3.4)	0	3 (9.7)	0	3 (7.5)
11	IGHV3‐11	3 (3.4)	2 (3.6)	1 (3.2)	1 (2.3)	2 (5)
12	IGHV3‐64	3 (3.4)	3 (5.4)	0	2 (4.5)	0
13	IGHV6‐1	3 (3.4)	3 (5.4)	0	0	3 (7.5)
14	IGHV1‐46	2 (2.3)	0	2 (6.5)	1 (2.3)	1 (2.5)
15	IGHV3‐15	2 (2.3)	2 (3.6)	0	0	1 (2.5)
16	IGHV3‐49	2 (2.3)	0	2 (6.5)	0	2 (5)
17	IGHV4‐30	2 (2.3)	1 (1.8)	1 (3.2)	0	2 (5)
18	IGHV4‐4	2 (2.3)	2 (3.6)	0	1 (2.3)	1 (2.5)
19	IGHV4‐b	2 (2.3)	0	2 (6.5)	1 (2.3)	1 (2.5)
20	*Others	3 (3.4)	2 (3.6)	1 (3.2)	1 (2.3)	2 (5)

Data are presented as number (%) of patients expressing the corresponding immunoglobulin variable region heavy chain (IGHV) member; All significant (P < 0.05) differences between groups are shown in bold. *Others represent IGHV3‐66, IGHV4‐59, and IGHV5‐a genes, each expressed in one patient. CLL, chronic lymphocytic leukemia.